Screener
Halozyme Therapeutics HALO Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's interest expense?
- Halozyme Therapeutics (HALO) reported interest expense of $5.59M in Q2 2026.
- How has Halozyme Therapeutics's interest expense changed year-over-year?
- Halozyme Therapeutics's interest expense increased by 27.2% year-over-year, from $4.39M to $5.59M.
- What is the long-term trend for Halozyme Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's interest expense has grown at a 24.6% compound annual growth rate (CAGR), from $7.53M to $18.13M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Halozyme Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude